{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T03:16:25Z","timestamp":1783134985456,"version":"3.54.6"},"reference-count":58,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"unspecified","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Postdoctoral Fellowship Program of CPSF","award":["GZB20250842"],"award-info":[{"award-number":["GZB20250842"]}]},{"name":"China National Nuclear Corporation Young Talent Program","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"National High-Level Hospital Clinical Research Funding","award":["2025-PUMCH-D-003"],"award-info":[{"award-number":["2025-PUMCH-D-003"]}]},{"name":"Beijing Nova Program and Beijing Nova Program Interdisciplinary Cooperation Project","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22507148"],"award-info":[{"award-number":["22507148"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372002"],"award-info":[{"award-number":["82372002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82502399"],"award-info":[{"award-number":["82502399"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nonprofit Central Research Institute Fund of the Chinese Academy of Medical Sciences","award":["2022-RC350-04"],"award-info":[{"award-number":["2022-RC350-04"]}]},{"name":"Fundamental Research Funds for the Central Universities, Peking Union Medical College","award":["3332025067"],"award-info":[{"award-number":["3332025067"]}]},{"name":"Fundamental Research Funds for the Central Universities, Peking Union Medical College","award":["3332025068"],"award-info":[{"award-number":["3332025068"]}]},{"name":"Fundamental Research Funds for the Central Universities, Peking Union Medical College","award":["3332025153"],"award-info":[{"award-number":["3332025153"]}]},{"name":"Fundamental Research Funds for the Central Universities, Peking Union Medical College","award":["3332025193"],"award-info":[{"award-number":["3332025193"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2025M773592 2025M781897"],"award-info":[{"award-number":["2025M773592 2025M781897"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tianjin Municipal Science and Technology Commission Grant","award":["25ZXRKSY00020"],"award-info":[{"award-number":["25ZXRKSY00020"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-026"],"award-info":[{"award-number":["2021-I2M-1-026"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-3-001"],"award-info":[{"award-number":["2021-I2M-3-001"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2023-I2M-2-006"],"award-info":[{"award-number":["2023-I2M-2-006"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2024-12M-ZH-009"],"award-info":[{"award-number":["2024-12M-ZH-009"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2025-I2M-XHJC-026"],"award-info":[{"award-number":["2025-I2M-XHJC-026"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2025-I2M-XHXX-098"],"award-info":[{"award-number":["2025-I2M-XHXX-098"]}]},{"name":"Beijing Natural Science Foundation","award":["7252206"],"award-info":[{"award-number":["7252206"]}]},{"name":"Beijing Natural Science Foundation","award":["L234044"],"award-info":[{"award-number":["L234044"]}]},{"name":"Beijing Natural Science Foundation","award":["L246051"],"award-info":[{"award-number":["L246051"]}]},{"name":"Beijing Natural Science Foundation","award":["L248087"],"award-info":[{"award-number":["L248087"]}]},{"name":"State Key Laboratory of Drug Regulatory Science Project","award":["2026SKLDRS03115"],"award-info":[{"award-number":["2026SKLDRS03115"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,2,18]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Programmed death-ligand 1 (PD-L1)-targeted radiopharmaceutical therapy (RPT) combined with immune checkpoint blockade (ICB) represents a promising combinatorial treatment because of the \u201cmagic\u201d bystander and abscopal effects of RPT. However, the overall efficacy of this combinatorial approach is often constrained by limited tumor retention and insufficient accumulation of existing radiopharmaceuticals. D-peptides, with their superior metabolic stability, offer a promising modality to overcome these limitations. We previously reported [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]\/[\n                      <jats:sup>64<\/jats:sup>\n                      Cu]DPA, which exhibited favorable in vivo stability. Nevertheless, its inadequate tumor retention hampers therapeutic efficacy and immune activation, highlighting the need for further optimization to achieve sustained target engagement.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Herein, fluorine modification-directed rational design was used to optimize DPA\u2019s target engagement and retention, thereby boosting its immune-activating potential in RPT. Following two rounds of screening, a series of fluorinated D-peptides was synthesized. Their in vivo performance was assessed by positron emission tomography (PET)\/CT imaging in tumor-bearing mice and subsequently in patients with cancer. The therapeutic efficacy of the corresponding\n                      <jats:sup>177<\/jats:sup>\n                      Lu-labeled fluorinated radiopharmaceuticals was further investigated to verify their potential in enhancing antitumor immunity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]D3-6, which incorporates a pentafluorinated phenylalanine residue, exhibited optimal tumor uptake and prolonged retention, achieving 22.43\u00b11.63%ID\/g at 4 hours post-injection. A preliminary clinical study further validated its diagnostic efficacy across multiple cancers. Additionally, [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]D3-6 boosted both local and systemic antitumor immunity and, in combination with anti-programmed cell death protein-1 therapy, elicited superior tumor inhibition.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study highlights the potential of fluorinated D-peptide radiopharmaceuticals as powerful PD-L1 targeting radiotheranostics, enabling more effective systemic antitumor efficacy in RPT and ICB combination therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-013732","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T14:40:20Z","timestamp":1773067220000},"page":"e013732","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Fluorination augments tumor engagement and antitumor immunity of a D-peptide-based radiotheranostic agent for combinatorial immune checkpoint blockade therapy"],"prefix":"10.1136","volume":"14","author":[{"given":"Siqi","family":"Zhang","sequence":"first","affiliation":[{"name":"State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Materia Medica, Beijing, China"},{"name":"Beijing Key Laboratory of Targeted Radiopharmaceutical Development and Translational Nuclear Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Materia Medica, Beijing, China"},{"name":"Beijing Key Laboratory of Targeted Radiopharmaceutical Development and Translational Nuclear Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingshuang","family":"Lu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Materia Medica, Beijing, China"},{"name":"Beijing Key Laboratory of Targeted Radiopharmaceutical Development and Translational Nuclear Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Materia Medica, Beijing, China"},{"name":"Beijing Key Laboratory of Targeted Radiopharmaceutical Development and Translational Nuclear Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Nanjing First Hospital, The First Affiliated Hospital With Nanjing Medical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Tianjin Cancer Hospital Airport Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Daytime Ward, Tianjin Cancer Hospital Airport Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qichen","family":"Hu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Materia Medica, Beijing, China"},{"name":"Beijing Key Laboratory of Targeted Radiopharmaceutical Development and Translational Nuclear Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyao","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Materia Medica, Beijing, China"},{"name":"Beijing Key Laboratory of Targeted Radiopharmaceutical Development and Translational Nuclear Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linger","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Materia Medica, Beijing, China"},{"name":"Beijing Key Laboratory of Targeted Radiopharmaceutical Development and Translational Nuclear Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuekai","family":"Song","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Materia Medica, Beijing, China"},{"name":"Beijing Key Laboratory of Targeted Radiopharmaceutical Development and Translational Nuclear Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Nanjing First Hospital, The First Affiliated Hospital With Nanjing Medical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Materia Medica, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2549-629X","authenticated-orcid":false,"given":"Kuan","family":"Hu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Materia Medica, Beijing, China"},{"name":"Beijing Key Laboratory of Targeted Radiopharmaceutical Development and Translational Nuclear Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"2026030907401068000_14.3.e013732.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00473-5"},{"key":"2026030907401068000_14.3.e013732.2","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1007\/s00259-024-06610-3","article-title":"Development of small-molecular-based radiotracers for PET imaging of PD-L1 expression and guiding the PD-L1 therapeutics","volume":"51","author":"Yang","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026030907401068000_14.3.e013732.3","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1007\/s00259-021-05672-x","article-title":"Preclinical and exploratory human studies of novel 68Ga-labeled D-peptide antagonist for PET imaging of TIGIT expression in cancers","volume":"49","author":"Wang","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026030907401068000_14.3.e013732.4","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1039\/C9CC00445A","article-title":"Developing native peptide-based radiotracers for PD-L1 PET imaging and improving imaging contrast by pegylation","volume":"55","author":"Hu","year":"2019","journal-title":"Chem Commun (Camb)"},{"key":"2026030907401068000_14.3.e013732.5","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1021\/acs.molpharmaceut.8b00399","article-title":"Peptide-Based 68Ga-PET Radiotracer for Imaging PD-L1 Expression in Cancer","volume":"15","author":"De Silva","year":"2018","journal-title":"Mol Pharm"},{"key":"2026030907401068000_14.3.e013732.6","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1021\/acs.molpharmaceut.3c00382","article-title":"Linear Peptide-Based PET Tracers for Imaging PD-L1 in Tumors","volume":"20","author":"Zhang","year":"2023","journal-title":"Mol Pharm"},{"key":"2026030907401068000_14.3.e013732.7","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41585-024-00924-5","article-title":"Immune effects of \u03b1 and \u03b2 radionuclides in metastatic prostate cancer","volume":"21","author":"Lunj","year":"2024","journal-title":"Nat Rev Urol"},{"key":"2026030907401068000_14.3.e013732.8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41392-024-01853-w","article-title":"Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade","volume":"9","author":"Zhao","year":"2024","journal-title":"Sig Transduct Target Ther"},{"key":"2026030907401068000_14.3.e013732.9","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1158\/1078-0432.CCR-22-0159","article-title":"A Paradigm of Cancer Immunotherapy Based on 2-[18F]FDG and Anti-PD-L1 mAb Combination to Enhance the Antitumor Effect","volume":"28","author":"Wen","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026030907401068000_14.3.e013732.10","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb3631","article-title":"Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade","volume":"13","author":"Patel","year":"2021","journal-title":"Sci Transl Med"},{"key":"2026030907401068000_14.3.e013732.11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s44178-023-00057-6","article-title":"Recent highlights of cancer immunotherapy","volume":"2","author":"Fan","year":"2023","journal-title":"Holist Integ Oncol"},{"key":"2026030907401068000_14.3.e013732.12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s44178-025-00175-3","article-title":"Real-world study of efficacy and safety of PD-1 antibody monotherapy and combination therapy in pediatric lymphoma patients","volume":"4","author":"Lan","year":"2025","journal-title":"Holist Integ Oncol"},{"key":"2026030907401068000_14.3.e013732.13","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21228721","article-title":"Mechanistic Insights into Synergy between Melanin-Targeting Radioimmunotherapy and Immunotherapy in Experimental Melanoma","volume":"21","author":"Malo","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026030907401068000_14.3.e013732.14","doi-asserted-by":"crossref","unstructured":"Li X , Wang C , Wu Y , et al . Self\u2010Powered \u03b1 Radionuclide Nanomedicine: Mitochondria\u2010Targeted Multimodal Energy Recycling for Amplified Radioimmunotherapy. Adv Mater Weinheim 2025;37. doi:10.1002\/adma.202504612","DOI":"10.1002\/adma.202504612"},{"key":"2026030907401068000_14.3.e013732.15","doi-asserted-by":"crossref","first-page":"304","DOI":"10.7150\/thno.45540","article-title":"PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a 177Lu-labeled \u03b1PD-L1 antibody","volume":"11","author":"Ren","year":"2021","journal-title":"Theranostics"},{"key":"2026030907401068000_14.3.e013732.16","doi-asserted-by":"crossref","DOI":"10.1186\/s40824-022-00290-6","article-title":"Alpha radionuclide-chelated radioimmunotherapy promoters enable local radiotherapy\/chemodynamic therapy to discourage cancer progression","volume":"26","author":"Zhang","year":"2022","journal-title":"Biomater Res"},{"key":"2026030907401068000_14.3.e013732.17","doi-asserted-by":"crossref","first-page":"101144","DOI":"10.1016\/j.nantod.2021.101144","article-title":"Radionuclide labeled gold nanoclusters boost effective anti-tumor immunity for augmented radio-immunotherapy of cancer","volume":"38","author":"Pei","year":"2021","journal-title":"Nano Today"},{"key":"2026030907401068000_14.3.e013732.18","doi-asserted-by":"publisher","DOI":"10.1515\/bmc-2015-0035"},{"key":"2026030907401068000_14.3.e013732.19","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5257.1854"},{"key":"2026030907401068000_14.3.e013732.20","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202200537","article-title":"D-Peptide and D-Protein Technology: Recent Advances, Challenges, and Opportunities","volume":"24","author":"Lander","year":"2023","journal-title":"Chembiochem"},{"key":"2026030907401068000_14.3.e013732.21","doi-asserted-by":"crossref","unstructured":"Zhang L , Zhang S , Wu W , et al . Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression. J Vis Exp 2023. doi:10.3791\/65047","DOI":"10.3791\/65047"},{"key":"2026030907401068000_14.3.e013732.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.09.016"},{"key":"2026030907401068000_14.3.e013732.23","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1021\/cbmi.4c00071","article-title":"Determining the Multivalent Effects of d-Peptide-Based Radiotracers","volume":"3","author":"Zhang","year":"2025","journal-title":"Chem Biomed Imaging"},{"key":"2026030907401068000_14.3.e013732.24","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1007\/s00259-022-05876-9","article-title":"Preclinical and first-in-human evaluation of 18F-labeled D-peptide antagonist for PD-L1 status imaging with PET","volume":"49","author":"Zhou","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026030907401068000_14.3.e013732.25","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1039\/D2CC06787K","article-title":"Recent advances in the synthesis of fluorinated amino acids and peptides","volume":"59","author":"Zhou","year":"2023","journal-title":"Chem Commun"},{"key":"2026030907401068000_14.3.e013732.26","doi-asserted-by":"publisher","DOI":"10.1039\/c1cs15241f"},{"key":"2026030907401068000_14.3.e013732.27","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/cbic.200300840","article-title":"Evaluation of the molecular interactions of fluorinated amino acids with native polypeptides","volume":"5","author":"J\u00e4ckel","year":"2004","journal-title":"Chembiochem"},{"key":"2026030907401068000_14.3.e013732.28","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1039\/b201097f","article-title":"Fluorinated amino acids in protein design and engineering","volume":"31","author":"Yoder","year":"2002","journal-title":"Chem Soc Rev"},{"key":"2026030907401068000_14.3.e013732.29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1070\/RC1974v043n01ABEH001787","article-title":"The Electronic Nature of Fluorine-containing Substituents","volume":"43","author":"Yagupol\u2019skii","year":"1974","journal-title":"Russ Chem Rev"},{"key":"2026030907401068000_14.3.e013732.30","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c01837"},{"key":"2026030907401068000_14.3.e013732.31","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/PAI.0000000000000572","article-title":"Characterization of PD-L1 Immunohistochemical Expression in Cell Blocks With Different Specimen Fixation and Processing Methods","volume":"27","author":"Lloyd","year":"2019","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"2026030907401068000_14.3.e013732.32","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1158\/1078-0432.CCR-25-0160","article-title":"68Ga-NK224 PET\/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study","volume":"31","author":"Zhao","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026030907401068000_14.3.e013732.33","doi-asserted-by":"crossref","first-page":"13345","DOI":"10.1007\/s00432-023-05142-x","article-title":"Programmed death-ligand 1 (PD-L1) expression in primary gastric adenocarcinoma and matched metastases","volume":"149","author":"Liu","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026030907401068000_14.3.e013732.34","doi-asserted-by":"crossref","DOI":"10.1038\/s41698-025-00901-0","article-title":"Immunotherapy in lung cancer brain metastases","volume":"9","author":"Paisana","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"2026030907401068000_14.3.e013732.35","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202400358","article-title":"Assessment of PD-L1 Expression in Non-Small Cell Lung Cancers Using [68Ga]Ga-DOTA-WL12 PET\/CT","volume":"8","author":"Wu","year":"2024","journal-title":"Small Methods"},{"key":"2026030907401068000_14.3.e013732.36","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-021-00211-8","article-title":"Predictive biomarkers of anti-PD-1\/PD-L1 therapy in NSCLC","volume":"10","author":"Niu","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"2026030907401068000_14.3.e013732.37","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.cytogfr.2017.06.011","article-title":"Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors","volume":"36","author":"Dammeijer","year":"2017","journal-title":"Cytokine Growth Factor Rev"},{"key":"2026030907401068000_14.3.e013732.38","doi-asserted-by":"publisher","DOI":"10.1172\/JCI99317"},{"key":"2026030907401068000_14.3.e013732.39","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/s43018-024-00734-z","article-title":"Modeling T cell temporal response to cancer immunotherapy rationalizes development of combinatorial treatment protocols","volume":"5","author":"Barboy","year":"2024","journal-title":"Nat Cancer"},{"key":"2026030907401068000_14.3.e013732.40","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0522-3"},{"key":"2026030907401068000_14.3.e013732.41","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41586-020-2056-8","article-title":"Peripheral T cell expansion predicts tumour infiltration and clinical response","volume":"579","author":"Wu","year":"2020","journal-title":"Nature New Biol"},{"key":"2026030907401068000_14.3.e013732.42","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1158\/2326-6066.CIR-24-0421","article-title":"The Spatial Organization of cDC1 with CD8+ T Cells is Critical for the Response to Immune Checkpoint Inhibitors in Patients with Melanoma","volume":"13","author":"Gobbini","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"2026030907401068000_14.3.e013732.43","doi-asserted-by":"publisher","DOI":"10.1038\/nm1554"},{"key":"2026030907401068000_14.3.e013732.44","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-017-0235-4","article-title":"Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy","volume":"5","author":"Sckisel","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2026030907401068000_14.3.e013732.45","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1007\/s00259-024-06743-5","article-title":"[18F]AlF-NOTA-PCP2: a novel PET\/CT tracer for enhanced PD-L1 heterogeneity imaging and comparative analysis with [18F]AlF-NOTA-WL12 in glioblastoma xenografts","volume":"51","author":"Wang","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026030907401068000_14.3.e013732.46","first-page":"251095","article-title":"Can [18F]FDG-PET\/CT Predict PD-L1 Expression in Head and Neck Carcinoma? A Head-to-Head Comparison with a Novel PD-L1 PET Tracer","volume":"66","author":"Wang","year":"2025","journal-title":"J Nucl Med"},{"key":"2026030907401068000_14.3.e013732.47","doi-asserted-by":"publisher","DOI":"10.1016\/S0958-1669(98)80011-6"},{"key":"2026030907401068000_14.3.e013732.48","doi-asserted-by":"publisher","DOI":"10.1002\/tcr.201600005"},{"key":"2026030907401068000_14.3.e013732.49","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-020-00781-4"},{"key":"2026030907401068000_14.3.e013732.50","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1021\/acs.accounts.1c00766","article-title":"Fluorination Promotes the Cytosolic Delivery of Genes, Proteins, and Peptides","volume":"55","author":"Lv","year":"2022","journal-title":"Acc Chem Res"},{"key":"2026030907401068000_14.3.e013732.51","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/s41467-018-03779-8","article-title":"The fluorination effect of fluoroamphiphiles in cytosolic protein delivery","volume":"9","author":"Zhang","year":"2018","journal-title":"Nat Commun"},{"key":"2026030907401068000_14.3.e013732.52","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/pep2.24184","article-title":"Fluorinated peptide biomaterials","volume":"113","author":"Sloand","year":"2021","journal-title":"Peptide Science"},{"key":"2026030907401068000_14.3.e013732.53","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/cmdc.201600132","article-title":"Fluorine Scan of Inhibitors of the Cysteine Protease Human Cathepsin\u2005L: Dipolar and Quadrupolar Effects in the \u03c0-Stacking of Fluorinated Phenyl Rings on Peptide Amide Bonds","volume":"11","author":"Giroud","year":"2016","journal-title":"ChemMedChem"},{"key":"2026030907401068000_14.3.e013732.54","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00386-6"},{"key":"2026030907401068000_14.3.e013732.55","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1053\/j.semnuclmed.2019.06.006","article-title":"Adverse Events of Diagnostic Radiopharmaceuticals: A Systematic Review","volume":"49","author":"Schreuder","year":"2019","journal-title":"Semin Nucl Med"},{"key":"2026030907401068000_14.3.e013732.56","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-00974-9"},{"key":"2026030907401068000_14.3.e013732.57","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2000487"},{"key":"2026030907401068000_14.3.e013732.58","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202301041","article-title":"In Situ Tumor Vaccine for Lymph Nodes Delivery and Cancer Therapy Based on Small Size Nanoadjuvant","volume":"19","author":"Zhang","year":"2023","journal-title":"Small"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013732","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T14:40:28Z","timestamp":1773067228000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":58,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,9]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/jitc-2025-013732"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013732","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}